The eukaryotic translation initiation factor 3 subunit B (EIF3B) is a critical component of the eIF3 complex, a multisubunit protein complex essential for initiating mRNA translation in eukaryotes. EIF3B plays a central role in ribosome recruitment to mRNA, scanning for start codons, and stabilizing interactions between other initiation factors. Antibodies targeting EIF3B are widely used in research to study its expression, localization, and function in protein synthesis regulation. Dysregulation of EIF3B has been implicated in various cancers, as overexpression is linked to enhanced cell proliferation, tumor growth, and poor prognosis in malignancies like prostate, breast, and colorectal cancers. EIF3B antibodies enable detection via techniques such as Western blotting, immunohistochemistry, and immunofluorescence, aiding investigations into its oncogenic mechanisms. Additionally, these antibodies help explore EIF3B's interactions within the eIF3 complex and its role in stress-responsive translation pathways. Recent studies also suggest EIF3B's involvement in viral infection responses, as some viruses hijack host translation machinery. While primarily utilized in basic research, EIF3B antibodies hold potential for diagnostic applications, particularly in cancer biomarker studies. However, variability in antibody specificity across isoforms or post-translationally modified forms remains a technical consideration.